Akebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
UPDATE: RBC Capital Issues Positive Comments on Akebia Therapeutics (AKBA), Believes Shares Could Trade Up $5 to $8 on Data
May 5, 2020 9:24 AM EDT(Updated - May 5, 2020 9:25 AM EDT)
(expanding comment)
RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating on Akebia Therapeutics (NASDAQ: AKBA)
The analyst comments "This morning AKBA announced positive topline results from the ph3 INNO2VATE studies (n=3,902) of vadadustat... More
Akebia Therapeutics (AKBA) Tops Q1 EPS by 15c
May 5, 2020 7:43 AM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.47), $0.15 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $88.5 million versus the consensus estimate of $77.48 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... More